Evaluation of diethylnitrosamine- or hepatitis B virus X gene-induced hepatocellular carcinoma with F-18-FDG PET/CT: A preclinical study

Abstract

The aim of this study was to evaluate whether the development of hepatocellular carcinoma (HCC) in murine models resembles tumor progression in humans, using non-invasive molecular imaging methods. Murine HCC models were generated by treating mice with diethylnitrosamine (DEN) or by the transgenic expression of hepatitis B virus X (HBx) protein (HBx-Tg model). Tumor development was detected using F-18-fluoro-2-deoxyglucose (F-18-FDG) positron emission tomography (PET)/computed tomography (CT) and magnetic resonance imaging (MRI). The histopathological changes and expression of glucose transporter 1 (Glut1) and hexokinase 2 (HK2) were evaluated using hematoxylin and eosin and immunohistochemical staining, respectively. Tumor lesions as small as 1 mm in diameter were detected by MRI. Tumor development was monitored using F-18-FDG PET/CT at 6.5-10 months after DEN treatment or 11-20 months after birth of the HBx-Tg model mice. A correlation study between the F-18-FDG uptake levels and expression levels of HK2 and Glut1 in developed HCC showed a high F-18-FDG uptake in poorly differentiated HCCs that expressed high levels of HK2, in contrast to that in well-differentiated tumors. The progression of primary HCCs resembling human HCC in murine models was detected and monitored by F-18-FDG PET/CT. The correlation between tumor size and SUVmax was verified in the two HCC models. To the best of our knowledge, this is the first study to demonstrate that in vivo(18)F-FDG uptake varies in HCCs according to differentiation grade in a preclinical study.